X0508 4 2025-12-26 0001531177 Sight Sciences, Inc. SGHT 0001870825 Badawi David C/O SIGHT SCIENCES, INC. 4040 CAMPBELL AVE., SUITE 100 MENLO PARK CA 94025 true true false false Chief Technology Officer false Common Stock 2025-12-26 4 M false 21270 0.23 A 1926769 D Stock Option (Right to Buy) 0.23 2025-12-26 4 M false 21270 0 D 2026-02-28 Common Stock 21270 21270 D Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. Includes (i) 1,758,996 shares of common stock, and (ii) 167,773 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. The Reporting Person previously reported a grant of 28,100 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 39,100 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 43,375 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. The grant of stock options ("Options") made to the Reporting Person vested and became exercisable as to 25% of the underlying shares on January 1, 2017, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on January 1, 2020. /s/Jeremy Hayden, Attorney-in-Fact for David Badawi 2025-12-30